Legal & General Group Plc Purchases 3,117 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legal & General Group Plc boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 151,550 shares of the medical equipment provider’s stock after purchasing an additional 3,117 shares during the quarter. Legal & General Group Plc owned about 0.22% of Lantheus worth $13,558,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of LNTH. Mirae Asset Global Investments Co. Ltd. raised its holdings in Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Empirical Asset Management LLC purchased a new position in shares of Lantheus in the fourth quarter worth $323,000. Focus Financial Network Inc. bought a new position in shares of Lantheus during the fourth quarter valued at $292,000. Harbor Capital Advisors Inc. increased its holdings in Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock worth $13,006,000 after buying an additional 16,466 shares in the last quarter. Finally, World Investment Advisors LLC purchased a new position in Lantheus in the 3rd quarter worth about $60,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by insiders.

Lantheus Stock Up 0.6 %

NASDAQ:LNTH opened at $102.78 on Wednesday. The business’s 50-day simple moving average is $94.48 and its two-hundred day simple moving average is $95.58. Lantheus Holdings, Inc. has a 52 week low of $59.56 and a 52 week high of $126.89. The stock has a market cap of $7.04 billion, a PE ratio of 17.10 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on LNTH. Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. B. Riley cut their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Finally, The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.